{"entity": "publication", "iuid": "6c0ae519022a4800be0250232691baa4", "timestamp": "2026-08-22T07:49:19.200Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/6c0ae519022a4800be0250232691baa4.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/6c0ae519022a4800be0250232691baa4"}}, "title": "The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer.", "authors": [{"family": "Li", "given": "Mei", "initials": "M"}, {"family": "Zelchan", "given": "Roman", "initials": "R"}, {"family": "Orlova", "given": "Anna", "initials": "A", "orcid": "0000-0001-6120-2683", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1c374f429702489494c05f84f298b4b7.json"}}], "type": "journal article", "published": "2022-10-10", "journal": {"title": "Biomedicines", "issn": "2227-9059", "volume": "10", "issue": "10", "issn-l": null}, "abstract": "Positron emission tomography (PET) incorporated with X-ray computed tomography (PET/CT) or magnetic resonance imaging (PET/MRI) is increasingly being used as a diagnostic tool for prostate cancer (PCa). In this review, we describe and evaluate the clinical performance of some Food and Drug Administration (FDA)-approved agents used for visualizing PCa: [18F]FDG, [11C]choline, [18F]FACBC, [68Ga]Ga-PSMA-11, [18F]DCFPyL, and [18F]-NaF. We carried out a comprehensive literature search based on articles published from 1 January 2010 to 1 March 2022. We selected English language articles associated with the discovery, preclinical study, clinical study, and diagnostic performance of the imaging agents for the evaluation. Prostate-specific membrane antigen (PSMA)-targeted imaging agents demonstrated superior diagnostic performance in both primary and recurrent PCa, compared with [11C]choline and [18F]FACBC, both of which target dividing cells and are used especially in patients with low prostate-specific antigen (PSA) values. When compared to [18F]-NaF (which is suitable for the detection of bone metastases), PSMA-targeted agents were also capable of detecting lesions in the lymph nodes, soft tissues, and bone. However, a limitation of PSMA-targeted imaging was the heterogeneity of PSMA expression in PCa, and consequently, a combination of two PET tracers was proposed to overcome this obstacle. The preliminary studies indicated that the use of PSMA-targeted scanning is more cost efficient than conventional imaging modalities for high-risk PCa patients. Furthering the development of imaging agents that target PCa-associated receptors and molecules could improve PET-based diagnosis of PCa.", "doi": "10.3390/biomedicines10102533", "pmid": "36289795", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9599369"}, {"db": "pii", "key": "biomedicines10102533"}], "notes": [], "created": "2026-08-21T13:01:16.213Z", "modified": "2026-08-21T13:01:16.231Z"}